May 18, 2006
For Immediate ReleaseNanomedicine Shakes Off Hype, Begins Realizing Potential, According to May MedMarkets and New Report from MedMarket Diligence (MMD)
The potential for nanomedicine, the medical application of nanotechnology, is vast, and has been touted as such almost endlessly since it was conceived. However, already on the market in the U.S. are wound dressings that exploit the antimicrobial properties of nanocrystalline silver, while nanotech-based products for drug delivery, materials technologies and other nanomedical applications are indeed real and in clinical trials now. These findings are presented in the May 2006 issue of MedMarkets, and a forthcoming report from MedMarket Diligence.
Foothill Ranch, CA, May 18, 2006 -- The application of nanoscale materials and devices to medical applications range from coatings to biosensors to drug delivery devices and ever more sophisticated diagnostics and therapeutics. Notwithstanding the enormous technical hurdles that have already been crossed in these developments, many remain before nanotechnology and microelectromechanical systems (MEMS) in medicine -- nanomedicine and micromedicine, respectively -- begin to fully demonstrate their clinical and market potential. Nonetheless, applications have entered clinical trials and are beginning to emerge and shake off some of the hype that has surrounded this nascent industry.
Near term applications include trojan Horse’ drug delivery in cancer, liposome-encapsulated drug delivery, and incorporation of MEMS in pacemaker accelerometers.
More advanced stage research projects, with anticipated near-term realization, include nanoparticles in drug delivery, targeted drug delivery in cancers, gold nanoshells for heat-killing of cancer cells, many types of cancer diagnostics, sensors for continuous blood glucose monitoring, MEMS in implantable pumps (e.g., insulin pumps), nanosensors to detect airborne pathogens and others.
On the more distant horizon, but actively under development, include practical applications of MEMS and nanotechnology such as a nano-battery for artificial retina, artificial viruses as gene carriers, MEMS in hearing aids and defibrillators, and applications in biomedical research: DNA/RNA/protein analysis, lab-on-a-chip, and others.
"The fields of MEMS and nanotechnology in medicine continue to drive an influx of capital and formation of companies like few other technologies in medicine in recent memory," says Patrick Driscoll, publisher of MedMarkets and president of MedMarket Diligence. "We have seen an extraordinary amount of activity since we began tracking and analyzing this market in 2001, and have been pleased to see the healthy development and investment driving new companies and emerging applications."
The May 2006 issue of MedMarkets examines several major areas of clinical application in MEMS and nanotechnology, highlighting companies active in the arena. MedMarket Diligence has also completed a worldwide analysis of the micro- and nanomedicine markets, with a forthcoming report detailed here.
MedMarket Diligence provides tactical decision-making solutions on medical technology to the medical products and investment industries. The company publishes the MedMarkets newsletter, a monthly analysis of the market implications of new medical technologies, and dedicated reports on technology markets. MedMarkets has identified hundreds of startup companies (many in stealth mode) and tracks market trends and opportunities emerging from changes in clinical practice, new technology development and other market drivers. For additional details, contact Patrick Driscoll at email or call 949-859-3401 or toll-free (in the U.S.). 1-866-820-1357.